In a note from January 07, 2020, the GMP analysts maintain CURALEAF in their BEST IDEA LIST.
We beleive the company’s highly strategic platform, industry-leading cash balance, strong M&A aptitude, and attractive valuation should drive a solid 2020 performance.
According to the analysts, Curaleaf is well positioned to lead the recreational market in MA and has a solid platform to capitalize on recreational in IL.
Analysts give a BUY rating with a target of $ 24.00
Analysts estimate that CURA currently has approximately $ 270M in cash which puts them far ahead of the competition.
Analysts give a BUY rating with a target of $ 24.00 to Curaleaf based on a multiple of 27.5X on the 2020 EBITDA target of $ 370M.
Consult the GMP report for more info
This article is written and published by The Cannabis Stock
Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result.
The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.